TherapeuticsMD Statistics
Total Valuation
TherapeuticsMD has a market cap or net worth of $23.15 million. The enterprise value is $21.76 million.
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TherapeuticsMD has 11.57 million shares outstanding. The number of shares has increased by 0.32% in one year.
| Current Share Class | 11.57M |
| Shares Outstanding | 11.57M |
| Shares Change (YoY) | +0.32% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 1.62% |
| Owned by Institutions (%) | 13.46% |
| Float | 9.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.66 |
| Forward PS | n/a |
| PB Ratio | 0.86 |
| P/TBV Ratio | 1.00 |
| P/FCF Ratio | 9.55 |
| P/OCF Ratio | 9.55 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 8.98 |
Financial Position
The company has a current ratio of 3.02, with a Debt / Equity ratio of 0.23.
| Current Ratio | 3.02 |
| Quick Ratio | 2.44 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.52 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2.41% and return on invested capital (ROIC) is -4.38%.
| Return on Equity (ROE) | -2.41% |
| Return on Assets (ROA) | -3.87% |
| Return on Invested Capital (ROIC) | -4.38% |
| Return on Capital Employed (ROCE) | -7.20% |
| Weighted Average Cost of Capital (WACC) | 5.70% |
| Revenue Per Employee | $3.02M |
| Profits Per Employee | -$569,000 |
| Employee Count | 1 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +104.08% in the last 52 weeks. The beta is 0.54, so TherapeuticsMD's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +104.08% |
| 50-Day Moving Average | 2.27 |
| 200-Day Moving Average | 1.58 |
| Relative Strength Index (RSI) | 33.76 |
| Average Volume (20 Days) | 21,121 |
Short Selling Information
The latest short interest is 47,542, so 0.41% of the outstanding shares have been sold short.
| Short Interest | 47,542 |
| Short Previous Month | 45,159 |
| Short % of Shares Out | 0.41% |
| Short % of Float | 0.50% |
| Short Ratio (days to cover) | 2.12 |
Income Statement
In the last 12 months, TherapeuticsMD had revenue of $3.02 million and -$569,000 in losses. Loss per share was -$0.05.
| Revenue | 3.02M |
| Gross Profit | 3.02M |
| Operating Income | -2.37M |
| Pretax Income | -653,000 |
| Net Income | -569,000 |
| EBITDA | -1.98M |
| EBIT | -2.37M |
| Loss Per Share | -$0.05 |
Full Income StatementBalance Sheet
The company has $7.48 million in cash and $6.10 million in debt, with a net cash position of $1.39 million or $0.12 per share.
| Cash & Cash Equivalents | 7.48M |
| Total Debt | 6.10M |
| Net Cash | 1.39M |
| Net Cash Per Share | $0.12 |
| Equity (Book Value) | 26.88M |
| Book Value Per Share | 2.32 |
| Working Capital | 9.66M |
Full Balance SheetCash Flow
| Operating Cash Flow | 2.42M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 384,000 |
| Net Borrowing | n/a |
| Free Cash Flow | 2.42M |
| FCF Per Share | $0.21 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -78.33% and -18.83%.
| Gross Margin | 100.00% |
| Operating Margin | -78.33% |
| Pretax Margin | -21.61% |
| Profit Margin | -18.83% |
| EBITDA Margin | -65.62% |
| EBIT Margin | -78.33% |
| FCF Margin | 80.21% |
Dividends & Yields
TherapeuticsMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.32% |
| Shareholder Yield | -0.32% |
| Earnings Yield | -2.46% |
| FCF Yield | 10.47% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 9, 2022. It was a reverse split with a ratio of 1:50.
| Last Split Date | May 9, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
TherapeuticsMD has an Altman Z-Score of -34.46 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -34.46 |
| Piotroski F-Score | 2 |
